NCT02035644 is a Phase 4 clinical trial of Jinlida granules in Type 2 Diabetes, sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT02035644?

NCT02035644 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT02035644?

Interventions in NCT02035644: Jinlida granules, placebo granules.

What condition does NCT02035644 study?

NCT02035644 studies Type 2 Diabetes, Dyslipidemia.

Is NCT02035644 still recruiting?

NCT02035644 is currently status unknown. Last updated 12 January 2014.

Last reviewed 2014-01-12 · How we verify

NCT02035644

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)

Status unknown Phase 4 Last updated 12 January 2014

What this trial tests

Phase 4 trial testing Jinlida granules in Type 2 Diabetes in 360 participants. Status unknown.

Timeline

1 February 2014

Primary endpoint
1 February 2015

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	360
Start date	1 February 2014
Primary completion	1 February 2015
Sites	1 location across China

Drugs / interventions tested

Jinlida granules — full drug profile →
placebo granules

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →
Dyslipidemia — all drugs for Dyslipidemia →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 20 to 70, any sex, with Type 2 Diabetes or Dyslipidemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

change in HbA1c levels
Time frame: 16 weeks

Sponsor's own description

The aim of the present study is to evaluate the efficacy and safety of Jinlida granules in patients with inadequately controlled type-2 diabetes and dyslipidemia under life style intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02035644 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 12 January 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02035644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing